Seminars in Nuclear Medicine
Volume 35, Issue 3 , Pages 197-201 , July 2005

Monitoring Cardiac Function in Patients Receiving Doxorubicin

  • Ping Lu, MD

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Ping Lu, MD, 255 Huguenot Street, Apartment 512, New Rochelle, NY 10801.

References 

  1. Anticancer drugs . In:  Harvey RA ,  Champe PC editor. Lippincott’s Illustrated Reviews (Pharmacology) . Philadelphia: JB Lippincott Company; 1992;
  2. Arola OJ , Saraste A , Pulkki K , et al.   Acute doxorubicin cardiotoxicity involves cardiomyocyte apoptosis . Cancer Res . 2000;60:1789–1792
  3. Nakamura T , Ueda Y , Juan Y , et al.   Fas-mediated apoptosis in adriamycin-induced cardiomyopathy in rats (In vivo study) . Circulation . 2000;102:572–578
  4. Khaw BA , Silva Da J , Petrov A , et al.   Indium 111 antimyosin and Tc-99m glucaric acid for noninvasive identification of oncotic and apoptotic myocardial necrosis . J Nucl Cardiol . 2002;9:471–481
  5. Von Hoff DD , Layard MW , Basa P , et al.   Risk factors for doxorubicin-induced congestive heart failure . Ann Intern Med . 1979;91:710–717
  6. Swain SM , Whaley FS , Ewer MS . Congestive heart failure in patients treated with doxorubicin a retrospective analysis of three trials . Cancer . 2003;97:2869–2879
  7. Shan K , Lincoff AM , Young JB . Anthracycline-induced cardiotoxicity . Ann Intern Med . 1996;125:47–58
  8. Steinherz LJ , Steinherz PG , Tan CT , et al.   Cardiac toxicity 4 to 20 years after completing anthracycline therapy . JAMA . 1991;266:1672–1677
  9. Lipshultz SE , Colan SD , Gelber RD , et al.   Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood . N Engl J Med . 1991;342:808–815
  10. Hequet O , Le QH , Mouller I , et al.   Subclinical late cardiomyopathy after doxorubicin therapy for lymphoma in adults . J Clin Oncol . 2004;22:1864–1870
  11. Jensen BV , Skovsgaard T , Nielsen SL . Functional monitoring of anthracycline cardiotoxicity (A prospective, blinded, long-term observational study of outcome in 120 patients) . Ann J Oncol . 2002;13:699–709
  12. Van Royen N , Jaffe CC , Krumholz HM , et al.   Comparison and reproducibility of visual echocardiographic and quantitative radionuclide left ventricular ejection fractions . Am J Cardiol . 1996;77:843:850
  13. Nousiainen T , Vanninen E , Jantunen E , et al.   Comparison of echocardiography and radionuclide ventriculography in the follow-up of left ventricular systolic function in adult lymphoma patients during doxorubicin therapy . J Intern Med . 2001;249:297–303
  14. Alexander J , Dainiak N , Berger HJ , et al.   Serial assessment of doxorubicin cardiotoxicity with quantitative radionuclide angiocardiography . N Engl J Med . 1979;300:278–283
  15. Piver MS , Marchetti DL , Parthasarathy KL , et al.   Doxorubicin hydrochloride (Adriamycin) cardiotoxicity evaluated by sequential radionuclide angiocardiography . Cancer . 1985;56:76–80
  16. Schwartz RG , McKenzie WB , Alexander J , et al.   Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy seven-year experience using serial radionuclide angiocardiography . Am J Med . 1987;82:1109–1118
  17. Mitani I , Jain D , Joska TM , et al.   Doxorubicin cardiotoxicity (prevention of congestive heart failure with serial cardiac function monitoring with equilibrium radionuclide angiocardiography in the current era) . J Nucl Cardiol . 2003;10:132–139
  18. Nousiainen T , Jantunen E , Vanninen E , et al.   Early decline in left ventricular ejection fraction predicts doxorubicin cardiotoxicity in lymphoma patients . Br J Cancer . 2002;86:1697–1700
  19. Steinherz LJ , Graham T , Hurwitz R , et al.   Guidelines for cardiac monitoring of children during and after anthracycline therapy (Report of the cardiology committee of the children’s cancer study group) . Pediatrics . 1992;89:942–949
  20. McKillop JH , Bristow MR , Goris ML , et al.   Sensitivity and specificity of radionuclide ejection fractions in doxorubicin cardiotoxicity . Am Heart J . 1983;106:1048–1056
  21. Palmeri ST , Bonow RO , Myers CE , et al.   Prospective evaluation of doxorubicin cardiotoxicity by rest and exercise radionuclide angiography . Am J Cardiol . 1986;58:607–613
  22. Lee BH , Goodenday LS , Muswick GJ , et al.   Alterations in left ventricular diastolic function with doxorubicin therapy . J Am Coll Cardiol . 1987;9:184–188
  23. Ganz WI , Sridhar KS , Forness TJ . Detection of early anthracycline cardiotoxicity by monitoring the peak filling rate . Am J Clin Oncol . 1993;16:109–112
  24. Cottin Y , Touzery C , Coudert B , et al.   Impairment of diastolic function during short-term anthracycline chemotherapy . Br Heart J . 1995;73:61–64
  25. Clements IP , Davis BJ , Wiseman GA . Systolic and diastolic cardiac dysfunction early after the initiation of doxorubicin therapy (Significance of gender and concurrent mediastinal radiation) . Nucl Med Commun . 2002;23:521–527
  26. Valdes Olmos RA , Carrio I , Hoefnagel CA , et al.   High sensitivity of radiolabeled antimyosin scintigraphy in assessing anthracycline related early myocyte damage preceding cardiac dysfunction . Nucl Med Commun . 2002;23:871–877
  27. Hiroe M , Ohta Y , Fujita N , et al.   Myocardial uptake of In-111 monoclonal antimyosin Fab in detecting doxorubicin cardiotoxicity in rats (Morphological and hemodynamic findings) . Circulation . 1992;86:1965–1972
  28. Estorch M , Carrio I , Berna L , et al.   Indium-111-antimyosin scintigraphy after doxorubicin therapy in patients with advanced breast cancer . J Nucl Med . 1990;31:1965–1969
  29. Carrio I , Lopez-Pousa A , Estorch M , et al.   Detection of doxorubicin cardiotoxicity in patients with sarcomas by indium-111-antimyosin monoclonal antibody studies . J Nucl Med . 1993;34:1503–1507
  30. Kremer LCM , Tiel-van Buul MMC , Ubbink MC , et al.   Indium-111-antimyosin scintigraphy in the early detection of heart damage after anthracycline therapy in children . J Clin Oncol . 1999;17:1208–1211
  31. Maini CL , Sciuto R , Ferraironi A , et al.   Clinical relevance of radionuclide angiography and antimyosin immunoscintigraphy for risk assessment in epirubicin cardiotoxicity . J Nucl Cardiol . 1997;4:502–508
  32. Wakasugi S , Wada A , Hasegawa Y , et al.   Detection of abnormal cardiac adrenergic neuron activity in adriamycin-induced cardiomyopathy with iodine-125-metaiodobenzylguanidine . J Nucl Med . 1992;33:208–214
  33. Valdes Olmos RA , Ten Bokkel Huinink WW , Greve JC , et al.   I-123 MIBG and serial radionuclide angiocardiography in doxorubicin-related cardiotoxicity . Clin Nucl Med . 1992;17:163–167
  34. Carrio I, Estorch M, Berna L, et al: Indium-111-antimyosin and iodine-123-MIBG studies in early assessment of doxorubicin cardiotoxicity. J Nucl Med 36:2044–2049
  35. Lekakis  , Prassopoulos V , Athanassiadis P , et al.   Doxorubicin-induced cardiac neurotoxicity (study with iodine 123-labeled metaiodobenzylguanidine scintigraphy) . J Nucl Cardiol . 1996;3:37–41
  36. Takano H , Ozawa H , Kobayashi I , et al.   Myocardial sympathetic dysinnervation in doxorubicin cardiomyopathy . J Cardiol . 1996;27:49–55
  37. Blankenberg F , Mari C , Strauss HW . Imaging cell death in vivo . Q J Nucl Med . 2003;47:337–348
  38. Bennink RJ , van den Hoff MJ , van Hemert FJ , et al.   Annexin V imaging of acute doxorubicin cardiotoxicity (apoptosis) in rats . J Nucl Med . 2004;45:842–848
  39. Lipshultz SE , Rifai N , Sallan SE , et al.   Predictive value of cardiac troponin T in pediatric patients at risk for myocardial injury . Circulation . 1997;96:2641–2648
  40. Herman EH , Zhang J , Lipshultz SE , et al.   Correlation between serum levels of cardiac troponin-T and the severity of the chronic cardiomyopathy induced by doxorubicin . J Clin Oncol . 1999;17:2237–2243
  41. Auner HW , Tinchon C , Linkesch W , et al.   Prolonged monitory of troponin T for the detection of anthracycline cardiotoxicity in adults with hematological malignancies . Ann Hematol . 2003;82:218–222
  42. Koh E , Nakamura T , Takahashi H . Troponin-T and brain natriuretic peptide as predictors for adriamycin-induced cardiomyopathy in rats . Circ J . 2004;68:163–167
  43. Cardinale D , Sandri MT , Colombo A , et al.   Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy . Circulation . 2004;109:2749–2754
  44. Mathew P , Suarez W , Kip K , et al.   Is there a potential role for serum cardiac troponin I as a marker for myocardial dysfunction in pediatric patients receiving anthracycline-based therapy? A pilot study . Cancer Invest . 2001;19:352–359
  45. Kismet E , Varan A , Ayabakan C , et al.   Serum troponin T levels and echocardiographic evaluation in children treated with doxorubicin . Pediatr Blood Cancer . 2004;42:220–224
  46. McDonagh TA , Cunningham AD , Morrison CE , et al.   Left ventricular dysfunction, natriuretic peptides, and mortality in an urban population . Heart . 2001;86:21–26
  47. Suzubi T , Hayashi D , Yamarak T , et al.   Elevated B-type natriuretic peptide levels after anthracycline administration . Am Heart J . 1998;136:362–363
  48. Nousianinen T , Jantunen E , Vanninen E , et al.   Natriuretic peptide as markers of cardiotoxicity during doxorubicin treatment for non-Hodgkin’s lymphoma . Eur J Haehmatol . 1999;62:135–141
  49. Meinardi MT, van Veldhuisen DJ, Gietema JA, et al: Prospective evaluation of early cardiac damage induced by epirubicin-containing adjuvant chemotherapy and locoregional radiotherapy in breast cancer patients. J Clin Oncol 19:2746–2753
  50. Theodoulou M , Hudis C . Cardiac profiles of liposomal anthracyclines . Cancer . 2004;100:2052–2063
  51. Swain SM , Vici P . The current and future role of dexrazoxane as a cardioprotectant in anthracycline treatment (Expert panel review) . J Cancer Res Clin Oncol . 2004;130:1–7

PII: S0001-2998(05)00015-2

doi: 10.1053/j.semnuclmed.2005.02.005

Seminars in Nuclear Medicine
Volume 35, Issue 3 , Pages 197-201 , July 2005

Article Tools

* Image Usage & Resolution